(2R)-2-氨基-4-甲基-3-硫基戊酸 | 98278-26-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2R)-2-氨基-4-甲基-3-硫基戊酸
• 中文别名: 亮氨酸,3-巯基-(6CI,9CI)
• 英文名称: 2-amino-3-mercapto-4-methylpentanoic acid
• 英文别名: DL-penicillamine；2-amino-3-mercapto-4-methyl-valeric acid；α-Amino-β-mercapto-isocapronsaeure；2-Amino-3-mercapto-4-methyl-valeriansaeure；β-Mercapto-leucin；2-Amino-4-methyl-3-sulfanylpentanoic acid
• CAS: 98278-26-3
• 化学式: C₆H₁₃NO₂S
• 分子量: 163.241
• InChiKey: WKYPQDXTDPCZHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 、 sodium 作用下， 生成 (2R)-2-氨基-4-甲基-3-硫基戊酸
  参考文献：
  名称：

  Crooks, Chemistry of Penicillin

  摘要：

  DOI：

文献信息

• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020065248A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及化合物的结构公式（I）：其中A1为亚甲基、乙烯基或丙烯基，A2为N或CR5，或其立体异构体形式、立体异构体混合物或药用盐形式，用作HCV NS3蛋白酶的抑制剂，以及包含相同化合物的药物组合物和诊断试剂盒，以及用于治疗病毒感染或作为测定标准或试剂的方法。
• [EN] COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS<br/>[FR] COMPOSITIONS POUR ADMINISTRER DES COMPOSÉS ANTISENS
  申请人：ENTRADA THERAPEUTICS INC

  公开号：WO2021127650A1

  公开（公告）日：2021-06-24

  Provided herein are compounds comprising cyclic cell penetrating peptides and antisense compounds. Also provided herein are methods of modulating splicing, inhibiting or regulating translation, mediating degradation, blocking expansions of nucleotide repeats, and treating disease using the aforementioned compounds.

  本文提供了包含环状细胞穿透肽和反义物的化合物。本文还提供了利用上述化合物调节剪接、抑制或调控翻译、介导降解、阻止核苷酸重复扩展以及治疗疾病的方法。
• Process for ring cleavage of thiazolidine derivatives
  申请人：Consortium fur Elektrochemische Industrie GmbH

  公开号：US06372912B1

  公开（公告）日：2002-04-16

  Process for the hydrolytic ring cleavage of thiazolidine derivatives to give 2-aminomercaptan derivatives and carbonyl compounds, which comprises bringing an aqueous solution of the thiazolidine derivative into contact with an acidic cation exchanger in the H+ form, giving a solution L1 which contains the carbonyl compound and eluting the cation exchanger with a suitable eluent, giving a solution L2 which contains the 2-aminomercaptan derivative.

  将噻唑啉衍生物水解环裂为2-氨基硫醇衍生物和羰基化合物的过程包括将噻唑啉衍生物的水溶液与H+形态的酸性阳离子交换树脂接触，得到含有羰基化合物的溶液L1，并用适当的洗脱剂洗脱阳离子交换树脂，得到含有2-氨基硫醇衍生物的溶液L2。
• Method for inducing cell death with carbonyl scavengers
  申请人：Wondrak T. Georg

  公开号：US20050197400A1

  公开（公告）日：2005-09-08

  Carbonyl scavengers, which have been recognized for their ability to react with reactive carbonyl species, have been implicated as agents that can accelerate or induce the death of abnormal cells without having a parallel effect on normal cells. As such, they are useful therapeutic agents in cases where the acceleration or induction of cell death is desirable, such as in cells where the normal apoptotic pathways have been disrupted and where hyperproliferative cell growth occurs.

  羰基清除剂，因其能够与反应性羰基物种反应而被认为是能够加速或诱导异常细胞死亡而不对正常细胞产生平行影响的剂量。因此，在需要加速或诱导细胞死亡的情况下，如正常凋亡途径被破坏并出现过度增殖的细胞中，它们是有用的治疗剂量。
• Peptide inhibitors of hepatitis C virus NS3 protein
  申请人：——

  公开号：US20020177725A1

  公开（公告）日：2002-11-28

  This invention relates to a novel class of peptides having the Formula (I): 1 Which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

  本发明涉及一类新型肽的公式(I)：1，其作为丝氨酸蛋白酶抑制剂具有用途，更具体地作为丙型肝炎病毒（HCV）NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗HCV感染的方法。